Sexual DesireDesire PLUSNCT05598008
Effects of Glucagon-like-Peptide-1 Analogues on Sexuality
An observational study of Sexual Desire, run by University Hospital, Basel, Switzerland at 1 site in Switzerland.
Trial summary
This study is to investigate the effects of GLP-1 analogues (combined with lifestyle interventions in comparison to lifestyle interventions only) on sexual desire, mood, quality of life, the reproductive axis, retinal vessel diameters, physical fitness (and semen, for men only) in overweight or obese men and women. Read more about this study
- Who is it for?
- Ages 18 to 75 yearsHealthy volunteers can take part
- Conditions the study is for
- Sexual Desire
- How many people
- 85 participants
- Where
- 1 siteSwitzerland
- Study dates
- 25 Nov 2022to 24 Oct 2025
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 75 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: The study population will consist of overweight men and women (BMI ≥ 27 kg/m2), which are seen at the obesity clinic of the University Hospital Basel and who wish to lose weight by lifestyle changes and optionally in combination with liraglutide treatment.
Who may be able to join
- BMI ≥ 27 kg/m2
- Willingness to lose weight by lifestyle changes only or by lifestyle changes plus GLP-1 analogue treatment as agreed in a routine clinical appointment
- Active sex life (sex with partner or masturbation ≥2x/month)
- Eugonadism:
- Men: morning total testosterone ≥12mmol/l or free testosterone ≥ 0.198 nmol/l if< 50 years old and ≥ 0.163 if > 50 years old
- Women: no primary or secondary amenorrhea (inclusive menopause) *Secondary amenorrhea is defined as "absence of menses for more than three months in women who previously had regular menstrual cycles or six months in women who had irregular menses".
Who cannot join
- Diabetes mellitus, HbA1c ≥ 6,5 %
- Previous use of GLP-1 analogues during last 2 months.
- Exogenous testosterone substitution
- Current illicit drug abuse
- Pregnancy
Trial locations and contacts
1 site in 1 country.
Switzerland1 site
University Hospital Basel, Endocrinology, Diabetes and Metabolism
Basel, 4031
About this study
Official title: The Desire PLUS Study - Effects of Glucagon-like-Peptide-1 Analogues on Sexuality: a Prospective Open-label Study
This study is to investigate the effects of GLP-1 analogues (combined with lifestyle interventions in comparison to lifestyle interventions only) on sexual desire, mood, quality of life, the reproductive axis, retinal vessel diameters, physical fitness (and semen, for men only) in overweight or obese men and women.
Read the detailed description
Glucagon-like peptide-1 (GLP-1) analogues are widely used for the treatment of type 2 diabetes mellitus due to its well-known insulinotropic effects as well as for the treatment of obesity due to its satiation-promoting and appetite- suppressant effects. The GLP-1 analogues are approved in patients with obesity (BMI ≥ 30 kg/m2) or who are overweight (BMI ≥ 27 kg/m2) with additional comorbidities, such as prediabetes, diabetes mellitus type 2, arterial hypertension or dyslipidemia. Beside its influence on the reward for palatable food, several studies have shown that GLP-1 analogues modulate the rewarding effects of addictive drugs such as alcohol, nicotine and cocaine. As a further natural reward, sexual desire could be affected by GLP-1 analogues likewise.
This study investigates the influence of GLP-1 analogues on sexuality in a population of overweight and obese participants. A treatment with a GLP-1 analogue combined with lifestyle modifications for weight reduction will be compared to weight reduction with conventional lifestyle modifications only. In the context of the increasing use of GLP-1 analogues, particularly in young people with reproductive desire, laboratory analyzes of the reproductive axis (hormones and sperm cells) will be part of this study to document a possible influence. Mood changes, physical activity and fitness and effects on microvascular endothelial functioning by measuring diameters of retinal vessels will be further investigated.
- Conditions
- Sexual Desire
- Keywords
- Glucagon-like-Peptide-1 (GLP-1), Glucagon-like peptide-1 (GLP-1) analogues, obesity, sexuality, Liraglutide (Saxenda®), obese men, reproductive axis, microvascular endothelial function, retinal vessels, physical activity, physical fitness, mood, sperm cells
- Medical subject headings
- Obesity, Sexuality, Motor Activity
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| GLP-1 Group | GLP-1 Group: receiving GLP-1 analogues for weight management in addition to conventional weight management (= lifestyle intervention plus GLP-1 analogues). Conventional weight management is conducted according to clinical guidelines (in both groups) and includes nutritional and exercise counselling, counselling by motivational coaches and/ or psychological support. Participants in the GLP-1 group will inject the medication themselves. | |
| Lifestyle group | Lifestyle group: using conventional weight management (= lifestyle intervention only). Conventional weight management is conducted according to clinical guidelines (in both groups) and includes nutritional and exercise counselling, counselling by motivational coaches and/ or psychological support. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in the German short version of the Sexual Desire Inventory (SDI-2) total score to assess sexual functioning
The SDI-2 consists of two items addressing frequency of sexual thoughts or activity, rated by a discrete score ranging from 0 to 7 (0 = not at all; 1 = once a month; 2 = once in two weeks; 3 = once a week; 4 = twice a week; 5 = three to four times a week; 6 = once a day; 7 = several times a day), and eight items rating the strengths of different types of sexual desires, rated by a continuous score ranging from 0 to 8 (0 = no desire to 8 = strong desire). The SDI-2 sum score ranges from 0 to 78. A positive score change indicates improvement of sexual desire.
Measured: At baseline (before start of treatment, at V1) and after 4-6 months of treatment (V2)
Secondary outcomes (25)
Change in the International Index of Erectile Function (IIEF-5) for men or Female Sexual Function Index (FSFI) for women questionnaire to assess sexual health and erectile function
The IIEF-5 is a 15-item self-evaluation scale; it provides pre-post treatment clinic evaluations of erectile function, orgasmic function, sexual desire, satisfaction in sexual intercourse and general satisfaction.
The FSFI is a 19-item self-reporting questionnaire; it measures dimensions such as desire, arousal, lubrication, orgasm, satisfaction, and pain during sexual activity.
Measured: At baseline (before start of treatment, at V1) and after 4-6 months of treatment (V2)
Change in the Patient Health Questionnaire (PHQ) -9 questionnaire to assess mood changes
The PHQ-9 tool may reflect patients' accounts of their experiences of depression and to assess severity of and treatment response. Each of the 9 items can be scored from 0 (not at all) to 3 (nearly every day).
Measured: At baseline (before start of treatment, at V1) and after 4-6 months of treatment (V2)
Change in the Patient Health Questionnaire (EQ-5D-5L) questionnaire to assess quality of life
The EQ-5D descriptive system comprises five dimensions: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression. The five levels in each dimension are worded as (1) 'not /no problems', (2) 'slight problems', (3) 'moderate problems', (4) 'severe problems', and (5) 'unable to' (mobility, self-care, usual activities), 'extreme' (pain/depression), or 'extremely' (anxiety/depression). The second part of the questionnaire comprises a standard vertical 20-cm VAS that is calibrated from 'the worst health you can imagine' (scored 0) at its base to 'the best health you can imagine' (scored 100) at its apex.
Measured: At baseline (before start of treatment, at V1) and after 4-6 months of treatment (V2)
Change in retinal vessel diameters to assess microvascular endothelial functioning
Change in retinal vessel diameters with the Static Retinal Vessel Analyzer (SVA-T, Imedos Systems UG, Jena, Germany). The system consists of a fundus camera (Topcon TRC NW8) and analyzing software (Visualis 3.2, Imedos Systems UG), allowing non-invasive and non-mydriatic assessment of retinal vessel diameters.
Measured: At baseline (before start of treatment, at V1) and after 4-6 months of treatment (V2)
Change in Oxytocin Level (IU) (hormone of the reproductive axis)
Oxytocin Level (hormone of the reproductive axis) will be measured in the blood.
Measured: At baseline (before start of treatment, at V1) and after 4-6 months of treatment (V2)
Change in semen concentration
Change in semen concentration
Measured: At baseline (before start of treatment, at V1) and after 4-6 months of treatment (V2)
Change in peak oxygen consumption during spiroergometry to assess physical fitness
Change in peak oxygen consumption during spiroergometry
Measured: At baseline (before start of treatment, at V1) and after 4-6 months of treatment (V2)
Change in maximum heart rate during spiroergometry
Change in maximum heart rate during spiroergometry
Measured: At baseline (before start of treatment, at V1) and after 4-6 months of treatment (V2)
Change in the Freiburg questionnaire for physical activity (FQPA)
The questionnaire consists of 12 items and allows a calculation of weighted metabolic equivalent tasks (MET) hours per week. The Physical Activity Questionnaire (FPAQ) is used to measure physical activity. Individuals are considered physically active when they achieved metabolic equivalent tasks (MET) minutes of 600 or more per week.
Measured: At baseline (before start of treatment, at V1) and after 4-6 months of treatment (V2)
Change in Testosterone level (nmol/l) (hormone of the reproductive axis)
Testosterone level (hormone of the reproductive axis) will be measured in the blood.
Measured: At baseline (before start of treatment, at V1) and after 4-6 months of treatment (V2)
Change in Estradiol level (pmol/l) (hormone of the reproductive axis)
Estradiol level (hormone of the reproductive axis) will be measured in the blood.
Measured: At baseline (before start of treatment, at V1) and after 4-6 months of treatment (V2)
Change in Sex hormone-binding globulin (SHBG) level (nmol/l) (hormone of the reproductive axis)
Sex hormone-binding globulin (SHBG) level (hormone of the reproductive axis) will be measured in the blood.
Measured: At baseline (before start of treatment, at V1) and after 4-6 months of treatment (V2)
Change in Luteinising hormone (LH) level (U/l) (hormone of the reproductive axis)
Luteinising hormone (LH) level (hormone of the reproductive axis) will be measured in the blood.
Measured: At baseline (before start of treatment, at V1) and after 4-6 months of treatment (V2)
Change in Follicle stimulating hormone (LH) level (U/l) (hormone of the reproductive axis)
Follicle stimulating hormone level (hormone of the reproductive axis) will be measured in the blood.
Measured: At baseline (before start of treatment, at V1) and after 4-6 months of treatment (V2)
Change in Prolactin level (yg/l) (hormone of the reproductive axis)
Prolactin level (hormone of the reproductive axis) will be measured in the blood immediately (10-20 min) after ejaculation.
Measured: At baseline (before start of treatment, at V1) and after 4-6 months of treatment (V2)
Change in semen motility
Change in semen motility
Measured: At baseline (before start of treatment, at V1) and after 4-6 months of treatment (V2)
Change in sperm fragmentation index (percentage of sperm with fragmented DNA)
Change in sperm fragmentation index (percentage of sperm with fragmented DNA)
Measured: At baseline (before start of treatment, at V1) and after 4-6 months of treatment (V2)
Change in body weight (kg)
Body weight is measured during the bioelectrical impedance analysis. The "InBody 720" device is used to perform the analysis.
Measured: At baseline (before start of treatment, at V1) and after 4-6 months of treatment (V2)
Change in body fat mass (%)
Body fat mass is measured during the bioelectrical impedance analysis. The "InBody 720" device is used to perform the analysis.
Measured: At baseline (before start of treatment, at V1) and after 4-6 months of treatment (V2)
Change in total body water (l)
Total body water is measured during the bioelectrical impedance analysis. The "InBody 720" device is used to perform the analysis.
Measured: At baseline (before start of treatment, at V1) and after 4-6 months of treatment (V2)
Change in extracellular water (%)
Extracellular water is measured during the bioelectrical impedance analysis. The "InBody 720" device is used to perform the analysis.
Measured: At baseline (before start of treatment, at V1) and after 4-6 months of treatment (V2)
Change in intracellular water (%)
Intracellular water is measured during the bioelectrical impedance analysis. The "InBody 720" device is used to perform the analysis.
Measured: At baseline (before start of treatment, at V1) and after 4-6 months of treatment (V2)
Change in hip/waist ratio
Hip/waist ratio is measured during the bioelectrical impedance analysis. The "InBody 720" device is used to perform the analysis.
Measured: At baseline (before start of treatment, at V1) and after 4-6 months of treatment (V2)
Change in Basal metabolic rate ((kcal/24h)
Basal metabolic rate is measured during the bioelectrical impedance analysis. The "InBody 720" device is used to perform the analysis.
Measured: At baseline (before start of treatment, at V1) and after 4-6 months of treatment (V2)
Change in visceral fat (%)
Visceral fat is measured during the bioelectrical impedance analysis. The "InBody 720" device is used to perform the analysis.
Measured: At baseline (before start of treatment, at V1) and after 4-6 months of treatment (V2)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted28 Oct 2022
- Study start25 Nov 2022
- Primary completion24 Oct 2025
- Study completion24 Oct 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Sexual DesireStudies of the same condition, open and under way.
- More trials run by University Hospital, Basel, SwitzerlandThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 85 participants (actual)
Sponsor and investigators
- Lead sponsor
- University Hospital, Basel, Switzerland
- Sponsor type
- University, hospital or other
- Collaborators
- Swiss National Science Foundation
- Responsible party
- Sponsor
- Investigators
- Bettina Winzeler, Dr. med., Principal investigator, Endocrinology, Diabetes and Metabolism, University Hospital Basel
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05598008
- Sponsor's protocol ID
- 2022-01367; kt22Winzeler
- Acronym
- Desire PLUS
- Status last verified
- Dec 2025
- First submitted
- 19 Oct 2022
- Last updated
- 23 Dec 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 23 Dec 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Desire PLUS Study - Effects of Glucagon-like-Peptide-1 Analogues on Sexuality: a Prospective Open-label Study
- ClinicalTrials.gov ID
- NCT05598008
- Acronym / sponsor ID
- Desire PLUS / 2022-01367; kt22Winzeler
- Conditions
- Sexual Desire
- Keywords
- Glucagon-like-Peptide-1 (GLP-1), Glucagon-like peptide-1 (GLP-1) analogues, obesity, sexuality, Liraglutide (Saxenda®), obese men, reproductive axis, microvascular endothelial function
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 85 participants (actual)
- Lead sponsor
- University Hospital, Basel, SwitzerlandUniversity, hospital or other
- Collaborators
- Swiss National Science Foundation
- Study start
- 25 Nov 2022 (actual)
- Primary completion
- 24 Oct 2025 (actual)
- Study completion
- 24 Oct 2025 (actual)
- First posted
- 28 Oct 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study is to investigate the effects of GLP-1 analogues (combined with lifestyle interventions in comparison to lifestyle interventions only) on sexual desire, mood, quality of life, the reproductive axis, retinal vessel diameters, physical fitness (and semen, for men only) in overweight or obese men and women.
Detailed description
Glucagon-like peptide-1 (GLP-1) analogues are widely used for the treatment of type 2 diabetes mellitus due to its well-known insulinotropic effects as well as for the treatment of obesity due to its satiation-promoting and appetite- suppressant effects. The GLP-1 analogues are approved in patients with obesity (BMI ≥ 30 kg/m2) or who are overweight (BMI ≥ 27 kg/m2) with additional comorbidities, such as prediabetes, diabetes mellitus type 2, arterial hypertension or dyslipidemia. Beside its influence on the reward for palatable food, several studies have shown that GLP-1 analogues modulate the rewarding effects of addictive drugs such as alcohol, nicotine and cocaine. As a further natural reward, sexual desire could be affected by GLP-1 analogues likewise.
This study investigates the influence of GLP-1 analogues on sexuality in a population of overweight and obese participants. A treatment with a GLP-1 analogue combined with lifestyle modifications for weight reduction will be compared to weight reduction with conventional lifestyle modifications only. In the context of the increasing use of GLP-1 analogues, particularly in young people with reproductive desire, laboratory analyzes of the reproductive axis (hormones and sperm cells) will be part of this study to document a possible influence. Mood changes, physical activity and fitness and effects on microvascular endothelial functioning by measuring diameters of retinal vessels will be further investigated.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| GLP-1 Group | – | –GLP-1 Group: receiving GLP-1 analogues for weight management in addition to conventional weight management (= lifestyle intervention plus GLP-1 analogues). Conventional weight management is conducted according to clinical guidelines (in both groups) and includes nutritional and exercise counselling, counselling by motivational coaches and/ or psychological support. Participants in the GLP-1 group will inject the medication themselves. |
| Lifestyle group | – | –Lifestyle group: using conventional weight management (= lifestyle intervention only). Conventional weight management is conducted according to clinical guidelines (in both groups) and includes nutritional and exercise counselling, counselling by motivational coaches and/ or psychological support. |
Who may qualify
- Ages
- 18 to 75 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- The study population will consist of overweight men and women (BMI ≥ 27 kg/m2), which are seen at the obesity clinic of the University Hospital Basel and who wish to lose weight by lifestyle changes and optionally in combination with liraglutide treatment.
Key inclusion criteria (6 listed)
- BMI ≥ 27 kg/m2
- Willingness to lose weight by lifestyle changes only or by lifestyle changes plus GLP-1 analogue treatment as agreed in a routine clinical appointment
- Active sex life (sex with partner or masturbation ≥2x/month)
- Eugonadism:
Key exclusion criteria (5 listed)
- Diabetes mellitus, HbA1c ≥ 6,5 %
- Previous use of GLP-1 analogues during last 2 months.
- Exogenous testosterone substitution
- Current illicit drug abuse
- Pregnancy
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Change in the German short version of the Sexual Desire Inventory (SDI-2) total score to assess sexual functioning
Time frame: At baseline (before start of treatment, at V1) and after 4-6 months of treatment (V2)
The SDI-2 consists of two items addressing frequency of sexual thoughts or activity, rated by a discrete score ranging from 0 to 7 (0 = not at all; 1 = once a month; 2 = once in two weeks; 3 = once a week; 4 = twice a week; 5 = three to four times a week; 6 = once a day; 7 = several times a day), and eight items rating the strengths of different types of sexual desires, rated by a continuous score ranging from 0 to 8 (0 = no desire to 8 = strong desire). The SDI-2 sum score ranges from 0 to 78. A positive score change indicates improvement of sexual desire.
25 secondary outcomes
Change in the International Index of Erectile Function (IIEF-5) for men or Female Sexual Function Index (FSFI) for women questionnaire to assess sexual health and erectile function
Time frame: At baseline (before start of treatment, at V1) and after 4-6 months of treatment (V2)
Change in the Patient Health Questionnaire (PHQ) -9 questionnaire to assess mood changes
Time frame: At baseline (before start of treatment, at V1) and after 4-6 months of treatment (V2)
Change in the Patient Health Questionnaire (EQ-5D-5L) questionnaire to assess quality of life
Time frame: At baseline (before start of treatment, at V1) and after 4-6 months of treatment (V2)
Change in retinal vessel diameters to assess microvascular endothelial functioning
Time frame: At baseline (before start of treatment, at V1) and after 4-6 months of treatment (V2)
Change in Oxytocin Level (IU) (hormone of the reproductive axis)
Time frame: At baseline (before start of treatment, at V1) and after 4-6 months of treatment (V2)
Change in semen concentration
Time frame: At baseline (before start of treatment, at V1) and after 4-6 months of treatment (V2)
Change in peak oxygen consumption during spiroergometry to assess physical fitness
Time frame: At baseline (before start of treatment, at V1) and after 4-6 months of treatment (V2)
Change in maximum heart rate during spiroergometry
Time frame: At baseline (before start of treatment, at V1) and after 4-6 months of treatment (V2)
Change in the Freiburg questionnaire for physical activity (FQPA)
Time frame: At baseline (before start of treatment, at V1) and after 4-6 months of treatment (V2)
Change in Testosterone level (nmol/l) (hormone of the reproductive axis)
Time frame: At baseline (before start of treatment, at V1) and after 4-6 months of treatment (V2)
Change in Estradiol level (pmol/l) (hormone of the reproductive axis)
Time frame: At baseline (before start of treatment, at V1) and after 4-6 months of treatment (V2)
Change in Sex hormone-binding globulin (SHBG) level (nmol/l) (hormone of the reproductive axis)
Time frame: At baseline (before start of treatment, at V1) and after 4-6 months of treatment (V2)
Change in Luteinising hormone (LH) level (U/l) (hormone of the reproductive axis)
Time frame: At baseline (before start of treatment, at V1) and after 4-6 months of treatment (V2)
Change in Follicle stimulating hormone (LH) level (U/l) (hormone of the reproductive axis)
Time frame: At baseline (before start of treatment, at V1) and after 4-6 months of treatment (V2)
Change in Prolactin level (yg/l) (hormone of the reproductive axis)
Time frame: At baseline (before start of treatment, at V1) and after 4-6 months of treatment (V2)
Change in semen motility
Time frame: At baseline (before start of treatment, at V1) and after 4-6 months of treatment (V2)
Change in sperm fragmentation index (percentage of sperm with fragmented DNA)
Time frame: At baseline (before start of treatment, at V1) and after 4-6 months of treatment (V2)
Change in body weight (kg)
Time frame: At baseline (before start of treatment, at V1) and after 4-6 months of treatment (V2)
Change in body fat mass (%)
Time frame: At baseline (before start of treatment, at V1) and after 4-6 months of treatment (V2)
Change in total body water (l)
Time frame: At baseline (before start of treatment, at V1) and after 4-6 months of treatment (V2)
Change in extracellular water (%)
Time frame: At baseline (before start of treatment, at V1) and after 4-6 months of treatment (V2)
Change in intracellular water (%)
Time frame: At baseline (before start of treatment, at V1) and after 4-6 months of treatment (V2)
Change in hip/waist ratio
Time frame: At baseline (before start of treatment, at V1) and after 4-6 months of treatment (V2)
Change in Basal metabolic rate ((kcal/24h)
Time frame: At baseline (before start of treatment, at V1) and after 4-6 months of treatment (V2)
Change in visceral fat (%)
Time frame: At baseline (before start of treatment, at V1) and after 4-6 months of treatment (V2)
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 23 Dec 2025.
Related trials for Sexual Desire
Not yet recruiting
A Clinical Trial to Evaluate the Effects of the NeuEve Dryness Treatment Kit on Vaginal Health, Comfort, and Quality of Life in Postmenopausal Women
Relieves Vaginal Dryness / Improves Self-Lubrication, Improves Strength & Elasticity of Vagina (Aka Collagen and Elastin)
Active, not recruiting
Effects of a Multi-Targeted Oral Supplement on Skin, Hair, Sleep, Energy, Cognition, Libido and Epigenetic Biological Clock Age
Skin Ageing, Healthy Ageing
Not yet recruiting
Transdermal Testosterone Gel for Female Sexual Interest and Arousal Disorder in Peri- and Post Menopause
Menopause, Sexual Dysfunction
Not yet recruiting
Radicle Women's Sexual HealthTM CIX: A Study Assessing the Impact of Health and Wellness Products on Sexual Health and Related Health Outcomes
Sexual Desire
Not yet recruitingPhase 1/2
BRE-06: Study to Increase Tolerance to Aromatase Inhibitors for Patients With Early-Stage Hormone Receptor Positive Breast Cancer Who Developed Hypoactive Sexual Desire Disorder
Early-stage Breast Cancer, Hypoactive Sexual Desire Disorder
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Bettina Winzeler, Dr. med. principal investigator
Endocrinology, Diabetes and Metabolism, University Hospital Basel
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Sexual Desire, run by University Hospital, Basel, Switzerland at 1 site in Switzerland.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 23 Dec 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Switzerland. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in the German short version of the Sexual Desire Inventory (SDI-2) total score to assess sexual functioning (time frame: At baseline (before start of treatment, at V1) and after 4-6 months of treatment (V2)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Dec 2025.